{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:39Z","timestamp":1790957919171,"version":"4.1.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Olorofim"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New antifungal agents are required to mitigate against azole-resistant Aspergillus and drug-resistant non-Aspergillus moulds. The novel orotomide, olorofim (F2G, Manchester, UK), has potent fungicidal activity against Aspergillus including azole-resistant Aspergillus fumigatus, Lomentospora prolificans and Scedosporium spp. Development of olorofim-specific clinical breakpoints\/epidemiological cut-off values requires reliable MIC data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Determine the in vitro activity of olorofim compared with standard antifungals against mould pathogens at an Australian hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Olorofim MICs were determined for 507 clinical mould isolates using the CLSI M38-A3 standard. MICs of amphotericin B, anidulafungin, posaconazole, voriconazole and isavuconazole were obtained using Sensititre\u2122 YeastOne YO10 and AUSNMRCI panels (Thermo-Fisher Scientific).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A. fumigatus sensu stricto was the commonest species (33.3%) followed by L. prolificans (18.3%), Scedosporium (11.4%) and Fusarium (6%) species. Olorofim modal MICs were \u22640.25 mg\/L (MIC90 0.25 mg\/L) for all Aspergillus except Aspergillus Section Usti (1 mg\/L); MICs for nine azole-resistant\/non-wild-type A. fumigatus ranged from 0.008 to 0.125 mg\/L. The MIC90 of olorofim for L. prolificans was 0.5 mg\/L, 0.25\u20130.5 mg\/L for Scedosporium spp. and 8 mg\/L for the F. solani complex but with modal MICs of 0.25 and 0.008 mg\/L for F. oxysporum and F. proliferatum complexes, respectively. For Verruconis gallopava (n\u200a=\u200a10), the olorofim MIC90 was 0.06 mg\/L (voriconazole MIC90 2 mg\/L, isavuconazole MICs of 4\u2013&amp;gt;8 mg\/L). Olorofim had little activity against other dematiaceous moulds including Exophiala species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Olorofim was highly active against Aspergillus spp. including azole-resistant A. fumigatus, L. prolificans, Scedosporium spp. and some Fusarium species with the new finding of potent activity against V. gallopava.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae267","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:46:19Z","timestamp":1721177179000},"page":"2611-2621","source":"Crossref","is-referenced-by-count":24,"title":["<i>In vitro<\/i>\n                    activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020\u20132023"],"prefix":"10.1093","volume":"79","author":[{"given":"Catriona L","family":"Halliday","sequence":"first","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]},{"name":"Sydney Institute for Infectious Diseases, University of Sydney , Westmead Hospital, Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch","family":"Tay","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Green","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Law","sequence":"additional","affiliation":[{"name":"F2G Ltd. , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Lopez","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Faris","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Meehan","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Harvey","sequence":"additional","affiliation":[{"name":"F2G Ltd. , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Birch","sequence":"additional","affiliation":[{"name":"F2G Ltd. , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-6603","authenticated-orcid":false,"given":"Sharon C A","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research\u2014New South Wales Health Pathology, Westmead Hospital , Westmead, NSW ,","place":["Australia"]},{"name":"Sydney Institute for Infectious Diseases, University of Sydney , Westmead Hospital, Westmead, NSW ,","place":["Australia"]},{"name":"F2G Ltd. , Manchester ,","place":["UK"]},{"name":"Faculty of Medicine & Health, University of Sydney , Camperdown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2024093023510659500_dkae267-B1","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.simyco.2021.100115","article-title":"Aspergillus fumigatus and aspergillosis: from basics to clinics","volume":"100","author":"Arastehfar","year":"2021","journal-title":"Stud Mycol"},{"key":"2024093023510659500_dkae267-B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B3","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/jac\/dkx028","article-title":"Changes in the epidemiological landscape of invasive mould infections and disease","volume":"72","author":"Lass-Fl\u00f6rl","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1055\/s-0039-3400957","article-title":"Phaeohyphomycosis","volume":"41","author":"Arcobello","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2024093023510659500_dkae267-B6","doi-asserted-by":"publisher","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2024093023510659500_dkae267-B7"},{"key":"2024093023510659500_dkae267-B8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024093023510659500_dkae267-B9","doi-asserted-by":"publisher","first-page":"e02546-20","DOI":"10.1128\/AAC.02546-20","article-title":"Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China","volume":"65","author":"Su","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B10","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B11","doi-asserted-by":"publisher","first-page":"e0123021","DOI":"10.1128\/JCM.01230-21","article-title":"Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States","volume":"59","author":"Badali","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2024093023510659500_dkae267-B12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/jof7040271","article-title":"In vitro antifungal drug resistance profiles of clinically relevant members of the Mucorales (Mucoromycota) especially with the newer triazoles","volume":"7","author":"Borman","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10096-015-2374-1","article-title":"Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification","volume":"34","author":"Araujo","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024093023510659500_dkae267-B14","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024093023510659500_dkae267-B15","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/mmy\/myx161","article-title":"In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi","volume":"56","author":"Biswas","year":"2018","journal-title":"Med Mycol"},{"key":"2024093023510659500_dkae267-B17","doi-asserted-by":"publisher","first-page":"e0278922","DOI":"10.1128\/spectrum.02789-22","article-title":"In vitro activity of the novel antifungal olorofim against Scedosporium and Lomentospora prolificans","volume":"11","author":"Georgacopoulos","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024093023510659500_dkae267-B18","doi-asserted-by":"publisher","first-page":"e01527-20","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018\u20132019 confirms uniform and broad-apectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jof7050378","article-title":"In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents","volume":"7","author":"Georgacopoulos","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B20","doi-asserted-by":"publisher","first-page":"e00256-21","DOI":"10.1128\/AAC.00256-21","article-title":"Antifungal susceptibility profiles of olorofim (formerly F901318) and currently available systemic antifungals against mold and yeast phases of Talaromyces marneffei","volume":"65","author":"Zhang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jof6030122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B22","doi-asserted-by":"publisher","first-page":"e00487-18","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/myc.13273","article-title":"In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes","volume":"64","author":"Badali","year":"2021","journal-title":"Mycoses"},{"key":"2024093023510659500_dkae267-B24","doi-asserted-by":"publisher","first-page":"e01157-17","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"key":"2024093023510659500_dkae267-B25","doi-asserted-by":"publisher","first-page":"e00999-18","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B26","doi-asserted-by":"publisher","first-page":"e0043421","DOI":"10.1128\/AAC.00434-21","article-title":"In vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J Infect Dis"},{"key":"2024093023510659500_dkae267-B28","author":"Maertens"},{"key":"2024093023510659500_dkae267-B29","author":"CLSI"},{"key":"2024093023510659500_dkae267-B30","author":"EUCAST"},{"key":"2024093023510659500_dkae267-B31","doi-asserted-by":"publisher","first-page":"100888","DOI":"10.1016\/j.lanwpc.2023.100888","article-title":"Invasive aspergillosis in adult patients in Australia and New Zealand: 2017\u20132020","volume":"40","author":"Tio","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2024093023510659500_dkae267-B32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/myc.13426","article-title":"Azole resistance in Aspergillus fumigatus. The first 2-year's data from the Danish National Surveillance Study, 2018\u20132020","volume":"65","author":"Risum","year":"2022","journal-title":"Mycoses"},{"key":"2024093023510659500_dkae267-B33","author":"CLSI"},{"key":"2024093023510659500_dkae267-B34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.pathol.2022.05.006","article-title":"Evaluation of a custom Sensititre YeastOne plate for susceptibility testing of isavuconazole and other antifungals against clinically relevant yeast and mould species in three Australian diagnostic mycology laboratories","volume":"54","author":"Halliday","year":"2022","journal-title":"Pathology"},{"key":"2024093023510659500_dkae267-B35","author":"CLSI"},{"key":"2024093023510659500_dkae267-B36","author":"CLSI"},{"key":"2024093023510659500_dkae267-B37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ijantimicag.2016.07.005","article-title":"Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations","volume":"48","author":"Halliday","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023510659500_dkae267-B38","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B39","doi-asserted-by":"publisher","first-page":"106105","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023510659500_dkae267-B40","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/jac\/dkaa562","article-title":"In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species","volume":"76","author":"Singh","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B41","doi-asserted-by":"publisher","first-page":"1291.e7","DOI":"10.1016\/j.cmi.2022.05.013","article-title":"In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B","volume":"28","author":"Escribano","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024093023510659500_dkae267-B42","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/jof8020150","article-title":"Increasing terbinafine resistance in Danish Trichophyton isolates 2019\u20132020","volume":"8","author":"Astvad","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B44","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciaa230","article-title":"Invasive aspergillosis due to Aspergillus section Usti: a multicenter retrospective study","volume":"72","author":"Glampedakis","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024093023510659500_dkae267-B45","author":"Esnault"},{"key":"2024093023510659500_dkae267-B46","author":"Cornelissen"},{"key":"2024093023510659500_dkae267-B47","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B48","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1093\/jac\/dku241","article-title":"Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy","volume":"69","author":"Hachem","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1086\/421950","article-title":"Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases","volume":"39","author":"Steinbach","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024093023510659500_dkae267-B50","doi-asserted-by":"publisher","first-page":"e02315-17","DOI":"10.1128\/AAC.02315-17","article-title":"Species identification and in vitro antifungal susceptibility of Aspergillus terreus species complex clinical isolates from a French multicenter study","volume":"62","author":"Imbert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B51","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/pathogens12040579","article-title":"Species distribution and antifungal susceptibilities of Aspergillus section Terrei isolates in clinical samples from the United States and description of Aspergillus pseudoalabamensis sp. nov","volume":"12","author":"Ca\u00f1ete-Gibas","year":"2023","journal-title":"Pathogens"},{"issue":"Suppl 7","key":"2024093023510659500_dkae267-B52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"2024093023510659500_dkae267-B53","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1093\/jac\/dky187","article-title":"Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates","volume":"73","author":"Talbot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B54","doi-asserted-by":"publisher","first-page":"e00632-19","DOI":"10.1128\/AAC.00632-19","article-title":"Cyp51a mutations, extrolite profiles, and antifungal susceptibility in clinical and environmental isolates of the Aspergillus viridinutans species complex","volume":"63","author":"Talbot","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B55","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1128\/AAC.00942-07","article-title":"Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification","volume":"52","author":"Alcazar-Fuoli","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023510659500_dkae267-B56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of Aspergillus","volume":"178","author":"Alastruey-Izquierdo","year":"2014","journal-title":"Mycopathologia"},{"key":"2024093023510659500_dkae267-B57","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024093023510659500_dkae267-B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1040841X.2018.1514366","article-title":"Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope\u00ae","volume":"45","author":"Seidel","year":"2019","journal-title":"Crit Rev Microbiol"},{"key":"2024093023510659500_dkae267-B59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jof7010023","article-title":"Scedosporium and Lomentospora infections: contemporary microbiological tools for the diagnosis of invasive disease","volume":"7","author":"Chen","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024093023510659500_dkae267-B60","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy","volume":"52","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023510659500_dkae267-B61","doi-asserted-by":"publisher","first-page":"784.e1","DOI":"10.1016\/j.cmi.2020.01.012","article-title":"Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope\u00ae registry 2008\u20132019","volume":"26","author":"Jenks","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024093023510659500_dkae267-B62","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","author":"Rivero-Menendez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/myc.13548","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus\/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species","volume":"66","author":"Wiederhold","year":"2023","journal-title":"Mycoses"},{"key":"2024093023510659500_dkae267-B64","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"Lim","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024093023510659500_dkae267-B65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mmcr.2016.12.006","article-title":"Verruconis gallopava cardiac and endovascular infection with dissemination after renal transplantation: case report and lessons learned","volume":"15","author":"Jennings","year":"2017","journal-title":"Med Mycol Case Rep"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2611\/59460012\/dkae267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2611\/59460012\/dkae267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T19:51:16Z","timestamp":1727725876000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/10\/2611\/7727908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae267","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,6]]}}}